U.S. markets closed

ImmunoCellular Therapeutics, Ltd. (IMUC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.7500-0.0600 (-7.41%)
At close: 3:44PM EST
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Currency in USD

Valuation Measures

Premium required to access annual data
Annual
Quarterly
Premium required to access monthly data
Monthly
Subscribe to Premium to download historical data
 
As of Date: 2/14/2021
Current
Market Cap (intraday) 5
1.16M
Enterprise Value 3
-1.69M
Trailing P/E
0.02
Forward P/E 1
N/A
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
0.35
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
0.30

Trading Information

Stock Price History

Beta (5Y Monthly) 1.50
52-Week Change 359.57%
S&P500 52-Week Change 339.88%
52 Week High 30.9800
52 Week Low 30.3900
50-Day Moving Average 30.6985
200-Day Moving Average 30.6615

Share Statistics

Avg Vol (3 month) 333.92k
Avg Vol (10 day) 310.03k
Shares Outstanding 54.19M
Float 4.18M
% Held by Insiders 10.00%
% Held by Institutions 10.00%
Shares Short (Oct 14, 2018) 4165.95k
Short Ratio (Oct 14, 2018) 44.13
Short % of Float (Oct 14, 2018) 43.96%
Short % of Shares Outstanding (Oct 14, 2018) 43.96%
Shares Short (prior month Sep 13, 2018) 4147.78k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Sep 15, 2020
Ex-Dividend Date 4N/A
Last Split Factor 21:10
Last Split Date 3Sep 15, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2017
Most Recent Quarter (mrq)Jun 29, 2018

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-88.07%
Return on Equity (ttm)-2,312.00%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -6.07M
Net Income Avi to Common (ttm)-9.03M
Diluted EPS (ttm)-2.6900
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.85M
Total Cash Per Share (mrq)0.68
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)9.53
Book Value Per Share (mrq)0.82

Cash Flow Statement

Operating Cash Flow (ttm)-10.93M
Levered Free Cash Flow (ttm)-9.22M